• Contact us
  • Customer support
  • Login
  • Home
  • Technology
    • Introduction
    • The Process
    • Clinical
    • Protocols
    • Get Started
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • Steen Solution™
    • Perfadex®
    • Perfadex® Plus
    • Silicone Tubing Set™
    • XVIVO LS™ & XVIVO Disposable Lung Set™
    • Organ Chamber™
    • Lung Cannula Set™
  • Knowledge
    • NOVEL study
    • Literature
    • Movies
  • Media
    • Videos
    • Insights
  • About us
    • About Xvivo
    • History
    • Training and workshops
    • Our market
    • News
    • Career
  • Corporate
    • Corporate
    • The share
    • Press releases
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports and prospectus
      • Interim reports
      • Annual reports
      • Prospectus
    • Financial presentations
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
    • Analyst Coverage
    • CODE OF CONDUCT
    • Privacy policy
    • Subscribe
    • Unsubscribe
    • Thank you
    • Error
XVIVO Perfusion
  • Contact us
  • Customer support
  • Login
  • Home
  • Technology
    • Introduction
    • The Process
    • Clinical
    • Protocols
    • Get Started
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • Steen Solution™
    • Perfadex®
    • Perfadex® Plus
    • Silicone Tubing Set™
    • XVIVO LS™ & XVIVO Disposable Lung Set™
    • Organ Chamber™
    • Lung Cannula Set™
  • Knowledge
    • NOVEL study
    • Literature
    • Movies
  • Media
    • Videos
    • Insights
  • About us
    • About Xvivo
    • History
    • Training and workshops
    • Our market
    • News
    • Career
  • Corporate
    • Corporate
    • The share
    • Press releases
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports and prospectus
      • Interim reports
      • Annual reports
      • Prospectus
    • Financial presentations
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
    • Analyst Coverage
    • CODE OF CONDUCT
    • Privacy policy
    • Subscribe
    • Unsubscribe
    • Thank you
    • Error
  • Corporate
  • The share
  • Press releases
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
  • Financial calendar
  • Financial reports and prospectus
    • Interim reports
    • Annual reports
    • Prospectus
  • Financial presentations
  • Corporate governance
    • Article of Association
    • General meetings
    • Board of Directors
    • Senior Management
    • Auditors
    • Board Committees
    • Board and Senior Management share holdings
    • Guidelines for remuneration
    • Nomination Committee
  • Analyst Coverage
  • CODE OF CONDUCT
  • Privacy policy
  • Subscribe
  • Unsubscribe
  • Thank you
  • Error

Clarification of news about two LS™ contract signed in Spain

XVIVO Perfusion (the Company) announced earlier today at the Company's website the news that two LS™ contracts was concluded in Spain, which were the first two LS™ contracts XVIVO Perfusion signed and the first lung evaluation machines (EVLP machines named LS™ and XPS™) to Spain.

XVIVO Perfusion clarifies that according to the Company's business model, the pricing strategy for capital goods, which are EVLP machines named LS ™ and XPS ™, is designed to allow the sale of capital goods to not have a significant financial impact on the company. According to the company's pricing strategy the future sales using the EVLP machines through sales of STEEN Solution ™ and related disposables is of financial importance for the Company.

As the number of clinics that perform lung transplants in Europe are only around 80, the deployment of EVLP machines is of significant importance because the sale of EVLP machines is a prerequisite for the company to monetize the use of these machines. In addition, these EVLP machines are the first to Spain, which carries a high proportion (13 percent in 2014 according GODT) of the total number of lung transplants in Europe. 

October 27, 2016
Gothenburg
XVIVO Perfusion AB (publ)

For further information please contact: Christoffer Rosenblad, CFO, +1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 5:15 p.m CET on October 27, 2016. This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.


XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in Denver, the USA. The XVIVO share is listed on NASDAQ First North premier and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se. XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424. Tel: 46 31 788 21 50. Fax: 46 31 788 21 69. E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com


Press release in PDF format


Xvivo Perfusion AB (publ), Box 53015, SE-400 14 Göteborg.
Org. Nr. 556561-0424.
Tel: 031-788 21 50.
Fax: 031-788 21 69.
E-mail: info@xvivoperfusion.com.
Hemsida: www.xvivoperfusion.com

Denna information skickades av Cision http://www.cisionwire.se
http://news.cision.com/xvivo-perfusion/r/clarification-of-news-about-two-ls--contract-signed-in-spain,c2110762

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in Denver, the USA. The XVIVO share is listed on NASDAQ First North premier and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se. XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424. Tel: 46 31 788 21 50. Fax: 46 31 788 21 69. E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com

About us

XVIVO Perfusion is a medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation.

Contact

Swedish Office
XVIVO Perfusion AB
Box 53015
SE-400 14 Göteborg
Sweden

Phone: +46 31 788 21 50
Fax: +46 31 788 21 69
info@xvivoperfusion.com

Newsletter

I have read and accepted XVIVO Perfusion's Privacy Policy

*By signing up to our newsletter you consent to XVIVO Perfusion sending you our insights newsletter and occasional additional communications. Your personal data will be transfered to a third party newsletter distributor engaged by XVIVO Perfusion. All processing of your personal data is in compliance with the XVIVO Perfusion Privacy Policy. For more information on how we use your personal data, please read XVIVO Perfusion’s Privacy policy

  • Home
  • Technology
  • Products
  • Knowledge
  • Media
  • About us
  • Corporate

Copyright © 2019 XVIVO Perfusion. All rights reserved.

Design mkmedia
To top

We use cookies to improve the user experience on XVIVO Perfusion. Read more about Cookies

Approve